The Generian team has developed an innovative approach to uncover first-in-class, gain-of-function drugs that activate key cellular networks linked to quality control and metabolism. Activation of these validated networks represents a unique approach with applicability across a broad range of chronic diseases. Led by top researchers in the fields of aging, small molecule drug development, and E3 ubiquitin ligase biology, Generian's platform will transform how we treat a wide array of both rare and common conditions using small molecules to reset and restore cellular homeostasis.